Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delamanid in pediatric multidrug-resistant tuberculosis with optimized background regimen
2012-004620-38Phase 2
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of delamanid in multidrug-resistant tuberculosis (MDR-TB), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Safety and tolerability of delamanid and its metabolites.
02
Drugs
delamanid
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on 2012-004620-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004620-38.